Company news

Biohaven Ltd. news in 2025

Biohaven Ltd.'s news releases, calls and decks from 2025, newest first.

View company

Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder

December 24, 2025

Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress

December 11, 2025

Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M

November 13, 2025

Biohaven Announces Pricing of $175 Million Public Offering of Common Shares

November 12, 2025

Biohaven Announces Proposed Public Offering of Common Shares

November 11, 2025

Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments

November 10, 2025

FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia

November 4, 2025

Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments

August 11, 2025

Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor

May 29, 2025

Biohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class BHV-1400 for IgA Nephropathy (IgAN)

May 28, 2025

Biohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to Treat a Wide Variety of Tumors

May 28, 2025

FDA Extends PDUFA Date of Biohaven's Troriluzole NDA for Rare Disease Spinocerebellar Ataxia

May 14, 2025

Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments

May 12, 2025

Biohaven Announces Investment up to $600 Million by Oberland Capital

April 28, 2025

Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting

April 5, 2025

Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300

March 3, 2025

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results

March 3, 2025

Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia

February 12, 2025

Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 8, 2025

Decks in 2025